Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Treasury Shares (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 7 years of Treasury Shares data on record, last reported at $1.1 million in Q3 2025.

  • For Q3 2025, Treasury Shares changed N/A year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, changed N/A, while the annual FY2024 figure was $314075.0, 60.98% down from the prior year.
  • Treasury Shares reached $1.1 million in Q3 2025 per VRDN's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.1 million in Q1 2025 and bottomed at $110375.0 in Q2 2023.
  • Average Treasury Shares over 3 years is $684466.2, with a median of $737021.5 recorded in 2023.
  • The widest YoY moves for Treasury Shares: up 167.64% in 2024, down 60.98% in 2024.
  • A 3-year view of Treasury Shares shows it stood at $804947.0 in 2023, then plummeted by 60.98% to $314075.0 in 2024, then surged by 247.19% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $1.1 million in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.